Cleerly Unveils PowerScribe Integration and Lesion-Level Reporting at RSNA 2025
New additions streamline data transfer with lesion details, helping make information more accessible for care teams
Cleerly is aware of the lawsuit filed by Heartflow. We are confident in our extensive and well-established intellectual property portfolio and the originality of our technology.
Cleerly has published landmark clinical science that has redefined how cardiovascular disease is understood and treated, which has formed the basis of our novel technologies that provide physicians with actionable insights into their patients’ heart health.
Cleerly was founded on a mission to create a world without heart attacks, and we have never been more focused in our mission and committed to the patients and physicians who count on us.
For any questions, please reach out to press@cleerlyhealth.com
New additions streamline data transfer with lesion details, helping make information more accessible for care teams
New Data from the CONFIRM2 International Registry Shows AI-QCT Improves Prediction of Major Cardiovascular Events from 62% to 75%
CONFIRM2 Registry Demonstrates Prognostic Value of AI-Based Plaque Characterization Beyond Stenosis Severity
Major Payors Embrace AI-Powered Cardiac Imaging, Expanding Access to Advanced Plaque Analysis